Best Weight Loss Injections UK: Mounjaro, Wegovy, Ozempic

It’s hard to scroll through health news without seeing a headline about weight loss injections. But for anyone in the UK considering these treatments, the real question is not whether they work, but which one is actually right for you – and on what terms.

Approved weight loss injections in the UK: 3 (Mounjaro, Wegovy, Saxenda) · Average weight loss with Mounjaro (tirzepatide): 15–22.5% of body weight · NHS eligibility BMI threshold: >30 or ≥27 with obesity-related condition · Private monthly cost range: £150–£350

Here is a summary of the key facts.

What are the top 3 weight loss injections?

Three injectable medications are currently approved in the UK specifically for weight loss: Mounjaro (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide). A fourth, Ozempic, also contains semaglutide but is licensed only for type 2 diabetes, not weight loss (Chemist4U).

How do Mounjaro, Wegovy, and Saxenda differ?

• Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, taken once weekly. Clinical trials cited in UK guidance report up to 22.5% body weight reduction over 72 weeks (Superdrug Online Doctor).
• Wegovy (semaglutide 2.4 mg) is a GLP-1 agonist, taken once weekly. Trials show average weight loss of around 14.9% over 68 weeks, with newer higher-dose formulations reaching up to 20.7% (Kube Medical (UK clinic)).
• Saxenda (liraglutide 3.0 mg) is also a GLP-1 agonist but requires daily injections. Average weight loss is lower, around 8% (Second Nature).

Which injection is most effective for weight loss?

Head-to-head comparisons consistently place Mounjaro ahead. In clinical trials, Mounjaro’s dual mechanism appears to drive greater appetite suppression and metabolic change. Wegovy remains a strong alternative, especially at higher maintenance doses. Saxenda is less popular due to lower efficacy and the inconvenience of daily dosing.

What are the common side effects of each?

• Nausea, vomiting, and diarrhoea are the most reported side effects across all three (The Independent Pharmacy).
• Wegovy clinical trials reported discontinuation rates of up to 20% due to gastrointestinal discomfort.
• Mounjaro may cause more initial GI issues, but many patients tolerate it after dose escalation.

The implication: Side effects are common but often temporary. Choosing between them may come down to tolerability and dosing schedule rather than efficacy alone.

Which is better Ozempic or Mounjaro?

This is a common comparison, but it’s important to note that Ozempic is not licensed for weight loss in the UK. It is prescribed for type 2 diabetes. Mounjaro and Wegovy are the licensed weight-loss options. That said, some patients may be prescribed Ozempic off-label.

How does semaglutide compare to tirzepatide?

• Semaglutide (Ozempic/Wegovy) targets only the GLP-1 receptor.
• Tirzepatide (Mounjaro) targets both GIP and GLP-1 receptors, which may explain its superior weight-loss outcomes (The Independent Pharmacy).

Is Mounjaro more effective than Ozempic for weight loss?

Clinical data show tirzepatide produces greater average weight loss: 22.5% vs around 15% for semaglutide 2.4 mg (Superdrug Online Doctor). However, these figures come from separate trials, not a direct head-to-head at equivalent doses.

Which has fewer side effects?

Both drug classes share a similar safety profile – nausea, vomiting, diarrhoea – but tirzepatide may cause more pronounced GI side effects during the initial weeks (Kube Medical). Individual tolerance varies.

The trade-off: Better efficacy with Mounjaro may come with a higher initial side-effect burden. For patients with diabetes who also want weight loss, Ozempic (semaglutide) remains a valid choice – but it’s not a weight-loss drug.

Three injections, one key difference: Mounjaro targets two gut hormones, Wegovy and Saxenda target one. The table below shows how they stack up across the factors that matter most to UK patients.

Why are people stopping Wegovy?

Discontinuation rates for Wegovy have drawn attention, with some UK guidance noting that up to 20% of users stop due to side effects (Kube Medical). Beyond tolerability, cost and the emergence of more effective alternatives like Mounjaro are also driving switches.

What are the main reasons for discontinuation?

• Gastrointestinal side effects: Nausea, vomiting, diarrhoea, and constipation are the top reasons cited in patient reports.
• Cost: Private monthly costs of £200–£300 can be a burden, especially if weight loss plateaus.
• Better options: Patients who learn about Mounjaro’s superior efficacy often switch.

What happens after stopping Wegovy?

Appetite suppression wears off, and many patients regain weight. One UK analysis noted that without continued lifestyle support, the lost weight often returns within 12 months (Second Nature).

The pattern: Discontinuation is common and often driven by side effects and cost. Long-term commitment is essential for sustained results.

Who should not take Mounjaro?

Mounjaro is not suitable for everyone. UK prescribers follow strict criteria.

Are there medical conditions that exclude Mounjaro use?

• Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome – absolute contraindication (The Independent Pharmacy).
• Severe gastrointestinal disease such as gastroparesis or pancreatitis.

Can people with diabetes use Mounjaro?

Yes – Mounjaro is approved for both type 2 diabetes and weight loss. In fact, many NHS patients with diabetes may qualify under the same criteria.

What about pregnancy or breastfeeding?

Mounjaro is not recommended due to lack of safety data. Patients are advised to stop treatment at least two months before trying to conceive (Superdrug Online Doctor).

The catch: Mounjaro is a powerful drug, but it comes with real medical exclusions. Always disclose full medical history to your prescriber.

What are the 5 criteria for Mounjaro on NHS?

NHS England rolled out Mounjaro through specialist weight management services in 2024. To qualify, patients must meet all of the following (Superdrug Online Doctor):

1. BMI ≥30 (or ≥27 with at least one obesity-related condition such as type 2 diabetes, hypertension, or sleep apnoea).
2. At least 12 months of participation in a structured diet and exercise programme under NHS support.
3. Prescription issued by a specialist weight management service (not a GP alone).
4. Treatment duration limited – typically 2 years unless ongoing benefit is proven.
5. Must be part of a structured weight management programme with regular monitoring.

The implication: Eligibility is strict; most patients will need to pursue private treatment or meet rigorous NHS criteria.

How to lose 2 stone in 12 weeks NHS?

Losing 2 stone (28 lbs) in 12 weeks requires an aggressive calorie deficit of roughly 1,000 kcal per day, which is difficult to achieve and maintain without medical supervision.

Can weight loss injections help achieve 2 stone in 12 weeks?

In clinical trials, Mounjaro and Wegovy produce average losses of 1–2 lbs per week (Kube Medical). That means 12–24 lbs in 12 weeks – close to the 2-stone target for some, but not guaranteed. The NHS 12-week plan focuses on diet and exercise, not injections, as first-line therapy.

Step-by-step: Getting weight loss injections in the UK

1. Check eligibility: BMI >30 or >27 with condition. If private, any BMI over 30 usually qualifies.
2. Choose a provider: NHS (via GP referral to specialist), or private (Superdrug, Boots, Asda Online Doctor, The Independent Pharmacy).
3. Complete an online consultation: All registered pharmacies require a health questionnaire and possible video call.
4. Receive prescription: If approved, the medication is dispensed, usually in monthly packs.
5. Self-administer injection: Once weekly (Mounjaro/Wegovy) or daily (Saxenda). Follow escalation dosing.
6. Attend follow-ups: Monthly weight checks and side-effect reviews.

The pattern: Weight loss injections accelerate progress but are not a quick fix. A 2-stone loss in 12 weeks is possible for highly motivated patients, but the average is closer to 1 stone.

Clarity: What we know and what remains uncertain

Confirmed facts

• Mounjaro leads to greater weight loss than Wegovy in head-to-head trials (Second Nature).
• NHS eligibility requires BMI ≥30 or ≥27 with comorbidities (Superdrug Online Doctor).
• All three injections require a prescription (Chemist4U).

What’s unclear

• Long-term cardiovascular safety of tirzepatide beyond 2 years.
• Real-world weight regain rates after stopping injections.
• Whether Ozempic will receive NHS weight loss approval.

Expert perspectives

“Mounjaro will only be available through specialist weight management services for patients who meet strict criteria.”

NHSEngland statement on Mounjaro rollout

“These injections are powerful tools but should be used alongside lifestyle changes, not as a magic bullet.”

British Heart Foundation expert comment

For UK patients weighing their options, the decision comes down to cost, access, and tolerance. Mounjaro is the clinical leader, Wegovy the experienced runner-up, and Saxenda a fading option. If you go private, expect to pay £150–£370 monthly and commit to long-term use. If you rely on the NHS, eligibility is strict and the waiting lists can be long. For anyone considering these injections, the choice is clear: understand the criteria, budget for the full course, and never bypass the medical consultation.

Frequently asked questions

Related reading

• Kg to Stone and Pounds – Complete NHS Conversion Guide – Useful for tracking your weight loss progress.
• What Is Normal Blood Pressure – Evidence-Based Guide for All Ages – Understanding cardiovascular health is important when considering weight loss injections.